{
  "url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024/regulation-3",
  "json_url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024/regulation-3.json",
  "legislation": "uksi/2024/248",
  "legislation_title": "The Misuse of Drugs and Misuse of Drugs (Designation) (England and Wales and Scotland) (Amendment and Revocation) Regulations 2024",
  "legislation_url": "https://openlegislation.uk/misuse-of-drugs-and-misuse-of-drugs-designation-england-and-wales-and-scotland-amendment-and-revocation-regulations-2024",
  "path": "regulation/3",
  "kind": "regulation",
  "number": "3",
  "heading": "Amendment of the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015",
  "text": "(1) The following amendments are made to Schedule 1 to the Misuse of Drugs (Designation) (England, Wales and Scotland) Order 2015 (which specifies controlled drugs to which section 7(4) of the Misuse of Drugs Act 1971 applies).\n(2) In paragraph 1(a)—\n(a) after “Bromazolam (8-bromo-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine)” insert “Brorphine”;\n(b) after “1,4-Butanediol” insert “Butonitazene”;\n(c) after “Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Clonitazene”;\n(d) after “Concentrate of poppy-straw” insert “Cumyl-PeGaClone”;\n(e) after “Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one)” insert—\n“Diphenidine\nEphenidine\nEthyleneoxynitazene”;\n(f) after “Etizolam” insert—\n“Etodesnitazene (etazene)\nEtonitazene”;\n(g) after “Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4] benzodiazepine)” insert “Flunitazene”;\n(h) after “Isopropylphenidate (IPP or IPPD)” insert “Isotonitazene”;\n(i) after “Methcathinone” insert “Methoxyphenidine”;\n(j) after “Metizolam (4-(2-Chlorophenyl)-2-ethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4] diazepine)” insert—\n“Metodesnitazene (metazene)\nMetonitazene”;\n(k) after “Propylphenidate” insert “Protonitazene”;\n(l) after “1-Cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)” insert—\n“N-Desethyl etonitazene\nN-Desethylisotonitazene\nN-Desethyl protonitazene”;\n(m) after “4-Methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (4,4’-DMAR)” insert—\n“N-Piperidinyl-etonitazene (etonitazepipne)\nN-Pyrrolidino-etonitazene (etoniazepyne)\nN-Pyrrolidino protonitazene”.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "footnote",
      "label": "f1",
      "text": "S.I. 2015/704, amended by S.I. 2017/632. There are other amending instruments, but none are relevant."
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2024/248/regulation/3",
    "retrieved_at": "2026-10-28T21:33:55.214598+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}